biostudies-literatureYadav AKIndian Council of Medical ResearchScience and Engineering Research Board, Govt. of India19https://www.ebi.ac.uk/biostudies/studies/S-EPMC9768065biostudies-literatureUnknown13(1)<i>Helicobacter pylori</i> (<i>H. pylori</i>) is one of most commonly found pathogen in the stomach. In spite of emergence of different treatment strategies, <i>H. pylori</i> infection remains difficult to treat. The bioengineered probiotic lactobacilli that could displace <i>H. pylori</i> and simultaneously present immunogenic peptides such as heparan sulphate binding protein (Hsbp) to elicit immune response could emerge as a potential therapeutic agent. The aim of this study was to discover the anti-<i>H. pylori</i> activities and faster exclusion of <i>H. pylori</i> from host cells by the recombinant strain of <i>Lactobacillus</i> expressing the immunogenic Hsbp protein. The results were promising and showed a 65% reduction in <i>H. pylori</i> adhesion after two hours of pre-incubation with recombinant-LGG and HeLa S3 cells, followed by the adhesion of <i>H. pylori</i> pathogen (<i>P</i> < 0.002). Additionally, 36% and 39% reduction were examined in co-incubation and post-incubation with recombinant-LGG, respectively. When challenged with <i>H. pylori</i>, the proinflammatory cytokine expression was also down regulated in recombinant-LGG treated HeLa S3 cells. This promising result provides a new insight of bioengineered probiotic lactobacilli which could displace <i>H. pylori</i> and simultaneously has immunogenic properties thereby may be useful to prevent <i>H. pylori</i> infection.<h4>Supplementary information</h4>The online version contains supplementary material available at 10.1007/s13205-022-03428-4.3 BiotechExpression of heterologous heparan sulphate binding protein of <i>Helicobacter pylori</i> on the surface of <i>Lactobacillus rhamnosus</i> GG.PMC9768065ECR/2017/0002703/1/3/PDF(7)/2013-HRDDebanth NRajkumar HKumar MKumar AYadav AKVarikuti SRfalseExpression of heterologous heparan sulphate binding protein of <i>Helicobacter pylori</i> on the surface of <i>Lactobacillus rhamnosus</i> GG.<i>Helicobacter pylori</i> (<i>H. pylori</i>) is one of most commonly found pathogen in the stomach. In spite of emergence of different treatment strategies, <i>H. pylori</i> infection remains difficult to treat. The bioengineered probiotic lactobacilli that could displace <i>H. pylori</i> and simultaneously present immunogenic peptides such as heparan sulphate binding protein (Hsbp) to elicit immune response could emerge as a potential therapeutic agent. The aim of this study was to discover the anti-<i>H. pylori</i> activities and faster exclusion of <i>H. pylori</i> from host cells by the recombinant strain of <i>Lactobacillus</i> expressing the immunogenic Hsbp protein. The results were promising and showed a 65% reduction in <i>H. pylori</i> adhesion after two hours of pre-incubation with recombinant-LGG and HeLa S3 cells, followed by the adhesion of <i>H. pylori</i> pathogen (<i>P</i> < 0.002). Additionally, 36% and 39% reduction were examined in co-incubation and post-incubation with recombinant-LGG, respectively. When challenged with <i>H. pylori</i>, the proinflammatory cytokine expression was also down regulated in recombinant-LGG treated HeLa S3 cells. This promising result provides a new insight of bioengineered probiotic lactobacilli which could displace <i>H. pylori</i> and simultaneously has immunogenic properties thereby may be useful to prevent <i>H. pylori</i> infection.<h4>Supplementary information</h4>The online version contains supplementary material available at 10.1007/s13205-022-03428-4.2023-01-01T00:00:00Z2023 Jan2025-05-18T11:45:04.276Z2025-05-18T11:45:04.276ZS-EPMC97680653656850110.1007/s13205-022-03428-4